Adelaide, South Australia wants to let the secret out, and be known as hub for medical devices, pharmaceuticals, biotechnology, and digital health. It boasts world-class research institutions, such as the University of Adelaide and SAHMRI, fostering innovation and collaboration. The city’s supportive government policies provide incentives, grants, and streamlined regulations for businesses. Adelaide’s skilled workforce, renowned for its expertise in health sciences, offers a talent pool to drive industry growth. Additionally, the city’s strategic location, advanced infrastructure, and strong healthcare ecosystem make it an ideal base for development, manufacturing, and market access, attracting companies in these sectors.
Australian Health Journal spoke to Jo Close, heading the Adelaide arm of MTPConnect about the opportunity its building through its role as the industry growth centre, to help increase commercialisation and collaboration across the sector, optimise the regulatory environment, improving workforce skills and access to markets globally.
One of the companies showing world leading MedTech capabilities arising from Adelaide is Additive Surgical, the first company in Australia to manufacture 3D Printed Titanium novel spinal implant technologies. Its mission is to manufacture the highest quality medical technology in Australia that positively impact the lives of people globally.
Australian Health Journal met with Co-founder and CEO Gibran Maher.
Maher states, “Additive Surgical is committed to supporting Australian innovation and works closely with the Australian clinicians, hospitals, research institutions and universities to innovate and manufacture locally.”
Maher points out the ability to compete is made possible through supportive collaboration with government, research and other enterprises seeking to learn from each other. But to truely compete in international markets, Australia’s needs to further strengthen its sovereign capability.
Currently Australia imports more than 80% of its medical devices. Large multinational companies have very strong market share in Australia and the profits from these companies are largely returned to their international shareholders.
Additive Surgical is committed to manufacturing in Australia, developing intellectual property in Australia and supporting Australian innovation and commercialisation.
You Might also like
-
Paramedics seek team-based primary health care pilots
The Chief Executive Officer of The Australasian College of Paramedicine, John Bruning spoke with Australian Health Journal about the following:
New models of care proposed for paramedics
Paramedicine pilot program in the pre-budget submission
Scope of how paramedics can support General Practice, and guidelines on safety and quality
Current limitations experienced by paramedics needing to be addressed by Government
Other health priorities hopefully addressed in Federal Budget.In the lead up to the Australian Federal Budget in May 2023, Australian Health Journal reached out to peak health industry bodies to hear about their priorities, either noted in pre-budget submissions lodged with Federal Government in January 2023 or in recent forums such as the Strengthening Medicare Taskforce.
-
Role of the Chief Nursing Officer
Professor Alison McMillan PSM spoke with Australian Health Journal about the role of Chief Nursing and Midwifery Officer at the Australian Government Department of Health and Aged Care.
Alison was appointed as our Chief Nursing and Midwifery Officer in November 2019.
In June 2021 Alison was awarded a Public Service Medal for outstanding public service to driving the Government’s national health response priorities during the COVID-19 pandemic, particularly to infection prevention measures.
-
Sharing the same goals in value-based procurement
Value-based procurement (VBP) is a journey, not a sprint. It’s about putting the patient at the centre of quality affordable healthcare through changes in procurement practices for medical technologies. Patient outcomes drive value and sustainability, not just price. The bigger picture indicates that VBP will create system cost saving through benefitting patients, rather than trying to attain the reverse – a win-win outcome.